Free Newsletter
Bacteria may help treat depression
An experimental cancer therapy may help point the way to a new treatment for clinical depression. The approach was inspired by work done by Dr. Mary O'Brien at the Royal Marsden Hospital in London, who injected lung cancer victims with Mycobacterium vaccae, a harmless version of bacteria that causes tuberculosis and leprosy. After the therapy was injected, the physician noted not only fewer symptoms of cancer, but an improvement in emotional health as well. Researchers followed that observation with an animal study to see if the bacteria would trigger an immune response that caused mice to produce additional amounts of serotonin, a neurotransmitter that is often in short supply among depressed patients. The positive response in mice, which responded with a stress-free attitude to swimming, is spurring a new look at a theory that ultra-hygienic environments for children may be contributing to higher rates of depression.
- read the report on the study from The Economist
Related Articles:
FDA approves Pristiq for depression. Report
Placebo effect sinks Corcept depression drug. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: